AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17909303 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine patch
Number of subjects: 116
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB graft with CD34(+) cell dose
Number of subjects: 31
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB graft with CD3(+) cell dose
Number of subjects: 31
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB graft with CD34(+)HLADR(+)CD38(+) progenitors
Number of subjects: 31
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution matching for HLA-class II (DRB1)
Number of subjects: 31
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB graft with higher cell doses of CD34(+), committed CD34(+) progenitors and CD3(+) T cells
Number of subjects: 31
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mortality
Number of subjects: 31
Study 17910637 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid engraftment
Number of subjects: 31
Study 17912368 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5g/d) + Conjugated linoleic acid (6g/d)
Number of subjects: 39
Study 17912368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17915028 — intervention group
Group type: COMPARATOR
Intervention: Electronic prescribing software with decision support at the point of care; details on dosage and duration not applicable as it is a software intervention.
Number of subjects: 0
Study 17915977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (dosing ranged from 25 mg every other day to 300 mg/day)
Number of subjects: 24
Study 17915977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 24
Study 17915977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day)
Number of subjects: 24
Study 17916243 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy within 24 hours of symptom onset
Number of subjects: 0
Study 17916243 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment with moxifloxacin followed by delayed elective cholecystectomy
Number of subjects: 0
Study 17920064 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 10 microg/kg
Number of subjects: 32
Study 17920064 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 15 microg/kg
Number of subjects: 32
Study 17920064 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab
Number of subjects: 32
Study 17923600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice referral
Number of subjects: 3010
Study 17923600 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (per 10-year increment)
Number of subjects: 3010
Study 17923600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum sodium concentration (per 5-mEq/L increment)
Number of subjects: 3010
Study 17923600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure (per 10-mm Hg increment)
Number of subjects: 3010
Study 17923600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum urea nitrogen concentration (per 10-mg/dL increment)
Number of subjects: 3010
Study 17923600 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of lipid-lowering drug therapy
Number of subjects: 3010
Study 17925413 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) with mean airway pressure increased to 40 cm H2O for 30 seconds
Number of subjects: 26
Study 17925413 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 26
Study 17934114 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (AdoMet) levels in patients with lung cancer
Number of subjects: 68
Study 17934114 — intervention group
Group type: COMPARATOR
Intervention: S-adenosylmethionine (AdoMet) levels in smokers with benign lung disease
Number of subjects: 68
Study 17934114 — intervention group
Group type: COMPARATOR
Intervention: S-adenosylmethionine (AdoMet) levels in healthy nonsmokers
Number of subjects: 68
Study 17934551 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.d. for 7 weeks
Number of subjects: 3431
Study 17934748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mitomycin C (0.01 nM) for 2 weeks followed by 0.1 to 100 microM mitomycin C; P-glycoprotein expression analysis using flow cytometry, immunoblotting, and RT-PCR.
Number of subjects: 30
Study 17934748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mitomycin C (0.01 nM) with verapamil (4 microM); P-glycoprotein expression analysis.
Number of subjects: 30
Study 17934748 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (0.1 nM) for 2 weeks; P-glycoprotein expression analysis.
Number of subjects: 30
Study 17934748 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trabeculectomy with mitomycin C; P-glycoprotein expression analysis in surgically removed Tenon tissue.
Number of subjects: 30
Study 17934748 — intervention group
Group type: COMPARATOR
Intervention: Patients not previously exposed to mitomycin C; P-glycoprotein expression analysis.
Number of subjects: 30
Study 17936715 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (vitrectomy, intravitreal triamcinolone acetonide injection, and macular laser photocoagulation)
Number of subjects: 24
Study 17938165 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 92
Study 17940483 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of anticoagulation (n = 103)
Number of subjects: 608
Study 17940483 — intervention group
Group type: COMPARATOR
Intervention: No resumption of anticoagulation (n = 120)
Number of subjects: 608
Study 17940483 — intervention group
Group type: COMPARATOR
Intervention: Normal D-dimer (n = 385)
Number of subjects: 608
Study 17942751 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal expansions of immunoglobulin M (IgM)(+)kappa(+)IgD(low/-)CD21(low)CD27(+) B cells in HCV(+)MC(+) subjects
Number of subjects: 0
Study 17942751 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen selection
Number of subjects: 0
Study 17942751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic B-cell stimulation
Number of subjects: 0
Study 17942751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermutated, marginal zone-like IgM(+)CD27(+) B cells
Number of subjects: 0
Study 17943084 — intervention group
Group type: EXPERIMENTAL
Intervention: Urotensin II (UTN)
Number of subjects: 122
Study 17951527 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox at 20 mg/kg per day
Number of subjects: 541
Study 17951527 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox at 30 mg/kg per day
Number of subjects: 541
Study 17951527 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 541
Study 17951527 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomized patients
Number of subjects: 541
Study 17954810 — intervention group
Group type: EXPERIMENTAL
Intervention: homocysteine level lowering therapy
Number of subjects: 0
Study 17954810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17957238 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A administered four weeks after BCG vaccination (short interval)
Number of subjects: 0
Study 17957238 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination alone
Number of subjects: 0
Study 17957238 — intervention group
Group type: COMPARATOR
Intervention: MVA85A administered many years after BCG vaccination (long interval)
Number of subjects: 0
Study 17959415 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 52
Study 17959855 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) at 0.15 mg/kg per day
Number of subjects: 24
Study 17959855 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) at 0.2 mg/kg per day
Number of subjects: 24
Study 17959855 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 24
Study 17959863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting intervention for 2 years
Number of subjects: 17
Study 17962585 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 17973983 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 200
Study 17973983 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 200
Study 17975162 — intervention group
Group type: EXPERIMENTAL
Intervention: Defucosylated anti-CCR4 monoclonal antibody KM2760
Number of subjects: 0
Study 17975162 — intervention group
Group type: EXPERIMENTAL
Intervention: Defucosylated anti-CCR4 monoclonal antibody KM2760 combined with immunomodulatory cytokines (interleukin-12, IFN-alpha-2b, IFN-gamma)
Number of subjects: 0
Study 17981652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir monotherapy, 1250 mg orally, BID for 3 weeks
Number of subjects: 15
Study 17981652 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 15
Study 17981912 — intervention group
Group type: EXPERIMENTAL
Intervention: PAVM embolisation
Number of subjects: 323
Study 17984237 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR 20 mg/q28d
Number of subjects: 56
Study 17984237 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR 30 mg/q28d
Number of subjects: 56
Study 17984237 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR 40 mg/q28d
Number of subjects: 56
Study 17984237 — intervention group
Group type: COMPARATOR
Intervention: Control of GH and IGF-I levels
Number of subjects: 56
Study 17984237 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tolerance
Number of subjects: 56
Study 17989313 — intervention group
Group type: EXPERIMENTAL
Intervention: BiRD (Biaxin [clarithromycin] 500 mg orally twice daily, lenalidomide [Revlimid] 25 mg orally daily on days 1 to 21, dexamethasone 40 mg orally once weekly)
Number of subjects: 72
Study 17990139 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17990291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) in polio survivors
Number of subjects: 24
Study 17990291 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) in healthy controls
Number of subjects: 24
Study 17990291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatiguing exercise in polio survivors
Number of subjects: 24
Study 17990291 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitch interpolation in polio survivors
Number of subjects: 24
Study 17990291 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of motor cortex excitability in polio survivors
Number of subjects: 24
Study 17990291 — intervention group
Group type: COMPARATOR
Intervention: Assessment of motor cortex excitability in healthy controls
Number of subjects: 24
Study 17996820 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers at hospital discharge
Number of subjects: 20118
Study 17996820 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers at hospital discharge
Number of subjects: 20118
Study 17999759 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly dosing of epoetin delta
Number of subjects: 0
Study 17999759 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly dosing of epoetin delta
Number of subjects: 0
Study 17999759 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta (all patients)
Number of subjects: 0
Study 17999759 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 0
Study 18000186 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 18000186 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 18000186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 18003886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 100 mg (1 dose) + 500 mg (3 doses)
Number of subjects: 33
Study 18003886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg (1 dose) + 1000 mg (3 doses)
Number of subjects: 33
Study 18003886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg (1 dose) + 2000 mg (3 doses)
Number of subjects: 33
Study 18003886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (all cohorts)
Number of subjects: 33
Study 18005455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 1.5 atm and 100% oxygen
Number of subjects: 18
Study 18005455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 1.3 atm and 24% oxygen
Number of subjects: 18
Study 18005455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental observations of children post-HBOT
Number of subjects: 18
Study 18008060 — intervention group
Group type: EXPERIMENTAL
Intervention: GCKR rs780094 A-allele
Number of subjects: 16853
Study 18021411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Goals
Number of subjects: 35
Study 18021411 — intervention group
Group type: COMPARATOR
Intervention: Structured Goals
Number of subjects: 35
Study 18021418 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative gamma camera
Number of subjects: 1
Study 18021496 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 400-800 mg from day 4 to 84)
Number of subjects: 477
Study 18021496 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 477
Study 18024436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening interpretation by 16 radiologists
Number of subjects: 135
Study 18024436 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up recommendations for positive cases
Number of subjects: 135
Study 18025537 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril therapy
Number of subjects: 2977
Study 18025537 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ACR (even within normal range)
Number of subjects: 2977
Study 18025537 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in ACR over time
Number of subjects: 2977
Study 18025796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 165
Study 18025796 — intervention group
Group type: COMPARATOR
Intervention: Caesarean section
Number of subjects: 165
Study 18026714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral taurine (TAU)
Number of subjects: 9
Study 18026714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (NAC)
Number of subjects: 9
Study 18026714 — intervention group
Group type: COMPARATOR
Intervention: Intralipid and heparin (IH) infusion
Number of subjects: 9
Study 18031749 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 264
Study 18031749 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions of MS by Viner
Number of subjects: 264
Study 18031749 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions of MS by Weiss
Number of subjects: 264
Study 18031749 — intervention group
Group type: COMPARATOR
Intervention: Other proposed definitions of MS
Number of subjects: 264
Study 18034602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 125
Study 18034602 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (self-monitored blood glucose, SMBG)
Number of subjects: 125
Study 18034602 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMS
Number of subjects: 125
Study 18034602 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMS and SMBG
Number of subjects: 125
Study 18039368 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers with COPD
Number of subjects: 114
Study 18039368 — intervention group
Group type: COMPARATOR
Intervention: Long-term quitters (> or =3.5 years)
Number of subjects: 114
Study 18039368 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 114
Study 18039992 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 133
Study 18039992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 18042798 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus steroids
Number of subjects: 160
Study 18042798 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 160
Study 18042798 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus steroids (related donors)
Number of subjects: 160
Study 18042798 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone (related donors)
Number of subjects: 160
Study 18042798 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus steroids (unrelated donors)
Number of subjects: 160
Study 18042798 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone (unrelated donors)
Number of subjects: 160
Study 18043905 — intervention group
Group type: COMPARATOR
Intervention: HbA1c 5.19-5.59% (top quintile)
Number of subjects: 27210
Study 18043905 — intervention group
Group type: COMPARATOR
Intervention: HbA1c 5.60-5.99%
Number of subjects: 27210
Study 18043905 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c range 4.50-7.00%
Number of subjects: 27210
Study 18043905 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 27210
Study 18045470 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced Breast MRI
Number of subjects: 500
Study 18048643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice daily)
Number of subjects: 119
Study 18050221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (2 infusions of 1,000 mg given 2 weeks apart)
Number of subjects: 1039
Study 18053191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with celecoxib (escalating doses of bortezomib on a weekly or twice-weekly schedule and celecoxib 200 mg to 400 mg twice daily)
Number of subjects: 18
Study 18053199 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia screening and treatment for those found to be infected
Number of subjects: 2526
Study 18053199 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (control group)
Number of subjects: 2526
Study 18053199 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants contacted post-recruitment
Number of subjects: 2526
Study 18053199 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants regarding consequences of untreated chlamydia
Number of subjects: 2526
Study 18054555 — intervention group
Group type: EXPERIMENTAL
Intervention: GB virus C (GBV-C) RNA positive patients
Number of subjects: 158
Study 18054555 — intervention group
Group type: COMPARATOR
Intervention: GB virus C (GBV-C) RNA negative patients
Number of subjects: 158
Study 18054887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bevacizumab (5 mg/kg)
Number of subjects: 10
Study 18055730 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia (7.5 mg bupivacaine)
Number of subjects: 70
Study 18055730 — intervention group
Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 70
Study 18055730 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 70
Study 18055730 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete breech presentation before external cephalic version
Number of subjects: 70
Study 18055865 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg every 7 +/- 2 days for 4 weeks; 900 mg 7 +/- 2 days later; followed by 900 mg every 14 +/- 2 days for a total treatment period of 52 weeks)
Number of subjects: 97
Study 18055865 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 97
Study 18056840 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multilineage dysplasia (MLD) in 1332 individuals receiving intensive AML therapy
Number of subjects: 1766
Study 18056840 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of MLD presence
Number of subjects: 1766
Study 18056840 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD association with unfavorable cytogenetic profile
Number of subjects: 1766
Study 18068035 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at 10 to 14 weeks after MI
Number of subjects: 322
Study 18068035 — intervention group
Group type: COMPARATOR
Intervention: Assessment at 2 to 4 weeks after MI
Number of subjects: 322
Study 18070995 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive therapy
Number of subjects: 0
Study 18070995 — intervention group
Group type: COMPARATOR
Intervention: Placebo-based antihypertensive therapy
Number of subjects: 0
Study 18071030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a plus oral doxycycline (100 mg daily for 4 months)
Number of subjects: 15
Study 18071034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 96
Study 18071034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 18071034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide treatment (meta-analysis)
Number of subjects: 96
Study 18074068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolift transvaginal mesh repair
Number of subjects: 123
Study 18077791 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 249
Study 18077791 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 249
Study 18078870 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (1.0 g/1000 kcal)
Number of subjects: 42
Study 18078870 — intervention group
Group type: COMPARATOR
Intervention: No plant sterols
Number of subjects: 42
Study 18078870 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 42
Study 18079362 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-30 (4 dose levels: 2, 4, 8, or 12 mg/kg)
Number of subjects: 24
Study 18079362 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-30 (6 weekly doses)
Number of subjects: 24
Study 18081737 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin
Number of subjects: 57
Study 18081737 — intervention group
Group type: COMPARATOR
Intervention: standard interferon/ribavirin
Number of subjects: 57
Study 18081737 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa-2b/ribavirin
Number of subjects: 57